Multivariate analysis of outcomes for recipients undergoing myeloablative conditioning followed by single UCB unit or double UCB unit transplantation
| Outcome measure . | Relative risk (95% CI) . | P . |
|---|---|---|
| GVHD, grade II-IV | ||
| Number of units | ||
| One | 1.0 | < .01 |
| Two | 2.1 (1.3-3.4) | |
| Transplantation-related mortality | ||
| Number of units | ||
| One | 1.0 | |
| Two | 0.8 (0.4-1.7) | .62 |
| CD34+ | ||
| Lowest quartile, < 2.6 × 105/kg | 1.0 | |
| Upper 3 quartiles, ≥ 2.6 × 105/kg | 0.5 (0.2-0.9) | .02 |
| Age, y | ||
| Younger than 10 | 1.0 | |
| 11-17 | 4.7 (1.5-14.7) | < .01 |
| 18 or older | 5.2 (1.6-16.6) | < .01 |
| Relapse, CR1 and CR2 only | ||
| Number of units | .04 | |
| One | 1 | |
| Two | 0.5 (0.2-1.0) | |
| Disease status | ||
| CR1 | 1 | |
| CR2 | 2.2 (1.0-4.8) | .06 |
| Leukemia-free survival, all patients | ||
| Number of units | .99 | |
| One | 1 | |
| Two | 1.0 (0.6-1.6) | |
| Disease status | < .01 | |
| CR1-2 | 1 | |
| CR3 relapse | 0.5 (0.3-0.8) | |
| CD34+ cell number, × 106/kg | ||
| Less than .25 | 1 | |
| .26-.41 | 1.3 (0.8-2.3) | .32 |
| .42-.65 | 1.3 (0.7-2.3) | .44 |
| More than .65 | 1.9 (1.1-3.6) | .03 |
| Outcome measure . | Relative risk (95% CI) . | P . |
|---|---|---|
| GVHD, grade II-IV | ||
| Number of units | ||
| One | 1.0 | < .01 |
| Two | 2.1 (1.3-3.4) | |
| Transplantation-related mortality | ||
| Number of units | ||
| One | 1.0 | |
| Two | 0.8 (0.4-1.7) | .62 |
| CD34+ | ||
| Lowest quartile, < 2.6 × 105/kg | 1.0 | |
| Upper 3 quartiles, ≥ 2.6 × 105/kg | 0.5 (0.2-0.9) | .02 |
| Age, y | ||
| Younger than 10 | 1.0 | |
| 11-17 | 4.7 (1.5-14.7) | < .01 |
| 18 or older | 5.2 (1.6-16.6) | < .01 |
| Relapse, CR1 and CR2 only | ||
| Number of units | .04 | |
| One | 1 | |
| Two | 0.5 (0.2-1.0) | |
| Disease status | ||
| CR1 | 1 | |
| CR2 | 2.2 (1.0-4.8) | .06 |
| Leukemia-free survival, all patients | ||
| Number of units | .99 | |
| One | 1 | |
| Two | 1.0 (0.6-1.6) | |
| Disease status | < .01 | |
| CR1-2 | 1 | |
| CR3 relapse | 0.5 (0.3-0.8) | |
| CD34+ cell number, × 106/kg | ||
| Less than .25 | 1 | |
| .26-.41 | 1.3 (0.8-2.3) | .32 |
| .42-.65 | 1.3 (0.7-2.3) | .44 |
| More than .65 | 1.9 (1.1-3.6) | .03 |
Models included the following variables: number of donors, recipient age, recipient weight, recipient sex, donor-recipient HLA disparity, recipient CMV serostatus, UCB graft cell doses (total NC, CD34, CD3), conditioning regimen, disease, remission status at transplantation, time from diagnosis to transplantation (for relapse) and GVHD prophylaxis. Acute GVHD was included as a time-dependent variable in each of the models.